title: Antidepressant drugs in cancer patients: the case of escitalopram.
authors.forename: Lamprini
authors.initials: L
authors.lastname: Tsali
authors.forename: Magdalini
authors.initials: M
authors.lastname: Bristianou
authors.forename: Antonis
authors.initials: A
authors.lastname: Valachis
authors.forename: Davide
authors.initials: D
authors.lastname: Mauri
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Barotsis
authors.forename: Evangelia
authors.initials: E
authors.lastname: Bellou
mesh_terms: D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000150:complications / Q000628:therapy; D015283:Citalopram / Q000009:adverse effects*; D005260:Female; D005909:Glioblastoma / Q000150:complications / Q000628:therapy; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors